Immunization Newsbriefs (c) Copyright Information Inc.,
Bethesda, MD. Brought to you by the National Network for
Immunization Information (NNii). Visit NNii's new website at

July 9, 2001

""Lack of Financing May End Trial of an AIDS Vaccine"
New York Times ( (07/09/01) P. C2; Pollack,

Pfizer, which has already paid Immune Response $47 million to put
the candidate HIV vaccine Remune through clinical trials, says it
has pulled its support of the drug because Immune Response has
failed to show that Remune is effective in delaying the onset of
AIDS.  Jonas Salk, the inventor of the polio vaccine, also
invented Remune, a killed virus vaccine just like the one for
polio.  University scientists studying Remune last year accused
Immune Response of trying to stop publication of a failed Remune
clinical trial, and the Food and Drug Administration warned the
company in 1995 not to manipulate data to show positive findings.
With only $12 million in cash, Immune is uncertain how to fund
continued clinical trials of Remune.